In today’s recent session, 0.72 million shares of the ATAI Life Sciences N.V (NASDAQ:ATAI) have been traded, and its beta is 1.19. Most recently the company’s share price was $1.58, and it changed around $0.01 or 0.32% from the last close, which brings the market valuation of the company to $312.33M. ATAI at last check was trading at a discount to its 52-week high of $2.85, offering almost -80.38% off that amount. The share price’s 52-week low was $1.03, which indicates that the recent value has risen by an impressive 34.81% since then. We note from ATAI Life Sciences N.V’s average daily trading volume that its 10-day average is 1.64 million shares, with the 3-month average coming to 2.88 million.
ATAI Life Sciences N.V stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended ATAI as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. ATAI Life Sciences N.V is expected to report earnings per share of -0.18 for the current quarter.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
Instantly ATAI has been showing a green trend so far today with a performance of 0.32% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.6600 on recent trading dayincreased the stock’s daily price by 4.82%. The company’s shares are currently up 18.42% year-to-date, but still up 16.67% over the last five days. On the other hand, ATAI Life Sciences N.V (NASDAQ:ATAI) is -13.46% down in the 30-day period. We can see from the shorts that 10.96 million shares have been sold at a short interest cover period of 2.38 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 73.67% from its current value. Analyst projections state that ATAI is forecast to be at a low of $6 and a high of $6.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
The year-over-year growth rate is expected to be -18.83%, down from the previous year.
Forecasts for the next quarter put sales growth at -100.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 18.62%. ATAI Life Sciences N.V earnings are expected to increase by 24.17% in 2025, but the outlook is positive 17.72% per year for the next five years.
ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 8.58% of ATAI Life Sciences N.V shares, and 29.19% of them are in the hands of institutional investors. The stock currently has a share float of 31.93%. ATAI Life Sciences N.V stock is held by 113.0 institutions, with WALLEYE CAPITAL LLC being the largest institutional investor. By 2024-06-30, it held 1.7226% of the shares, which is about 2.76 million shares worth $3.67 million.
MORGAN STANLEY, with 1.6952% or 2.72 million shares worth $3.62 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Inception Portfolio and AdvisorShares Psychedelics ETF were the top two Mutual Funds as of Dec 31, 2024. The former held 511.99 shares worth $0.81 million, making up 0.26% of all outstanding shares. On the other hand, AdvisorShares Psychedelics ETF held roughly 408.76 shares worth around $0.65 million, which represents about 0.21% of the total shares outstanding.
